ProbarE i Stockholm AB
- Address
- lock Available on a paid plan
Cardiovascular Diseases
ProbarE i Stockholm explores cardiovascular health through studies of metabolic and renal conditions that impact heart function, aiming to improve prevention and management strategies.
- Chronic kidney disease
- Diabetes Mellitus, Type 1
- Beta‑cell function preservation
The site’s interdisciplinary approach links metabolic research to heart disease risk, supporting patients in Stockholm with cutting‑edge investigations.
Immune System Diseases
Clinical programs target immune‑mediated disorders by evaluating novel biologics and small molecules that modulate inflammatory pathways.
- Birch pollen‑induced allergic rhinoconjunctivitis
- Chronic obstructive pulmonary disease (COPD)
- Type 2 inflammation in respiratory disease
ProbarE i Stockholm collaborates with industry partners to test therapies that could reduce disease burden for patients with allergic and inflammatory conditions.
Nervous System Diseases
The laboratory conducts research on neurological disorders, focusing on acute symptom relief and quality‑of‑life improvements.
- Acute migraine (with or without aura)
- Neuropathic pain associated with migraine
By assessing fast‑acting treatments, ProbarE i Stockholm aims to provide new options for individuals suffering from debilitating headache disorders.
Nutritional and Metabolic Diseases
Studies address metabolic dysfunction and its complications, seeking therapies that modify disease progression and organ damage.
- Diabetes Mellitus, Type 1
- Chronic kidney disease
- Urine albumin‑creatinine ratio as a marker of renal health
The site’s work supports patients by exploring interventions that could preserve kidney function and improve metabolic control.
Respiratory Tract Diseases
Research initiatives target respiratory conditions, evaluating treatments that lower exacerbation rates and alleviate allergic symptoms.
- Chronic obstructive pulmonary disease (COPD)
- Birch pollen‑induced allergic rhinoconjunctivitis
- Asthma‑related respiratory inflammation
ProbarE i Stockholm’s trials aim to reduce hospital visits and improve daily breathing comfort for affected individuals.
Immune System Phenomena
The facility investigates immune system mechanisms such as cytokine signaling and receptor antagonism to guide therapeutic development.
- Kappa opioid receptor antagonism
- IL‑33 pathway inhibition
- Type 2 immune response modulation
Insights from these studies help shape future drugs that can more precisely target immune dysregulation.
Mental Disorders
A core focus is on major depressive disorder, exploring adjunctive agents that address symptoms like anhedonia and insomnia.
- Major Depressive Disorder with moderate‑to‑severe anhedonia
- Major Depressive Disorder with insomnia symptoms
- Adjunctive therapy to existing antidepressants
ProbarE i Stockholm’s trials seek to enhance treatment response for patients who have not benefited from standard antidepressant regimens.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Janssen Cilag International1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ProbarE i Stockholm AB
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Sep 2023 | Sep 2025 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine | 2 | Unknown | 2024-07-18 | 2024-09-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.